Measuring Opioid Withdrawal in a Phase 3 Study of a New Analgesic, NKTR-181 (Oxycodegol), in Patients with Moderate to Severe Chronic Low Back Pain

OBJECTIVE: To evaluate the SUMMIT-07 trial opioid withdrawal results of NKTR-181 (oxycodegol), a new molecular entity mu-opioid receptor agonist. DESIGN: Phase 3, enriched-enrollment, double-blind, randomized-withdrawal study in patients with chronic low back pain (CLBP). SETTING: Conducted in the U...

Descripción completa

Detalles Bibliográficos
Autores principales: Henningfield, Jack E, Gudin, Jeffrey, Rauck, Richard, Gimbel, Joseph, Tagliaferri, Mary, Doberstein, Stephen K, Di Fonzo, Carlo, Lu, Lin, Katz, Nathaniel, Siddhanti, Suresh, Schnoll, Sidney
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Opioids & Substance Use Disorders Section
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7530570/
https://www.ncbi.nlm.nih.gov/pubmed/32150255
http://dx.doi.org/10.1093/pm/pnz326

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7530570/
https://www.ncbi.nlm.nih.gov/pubmed/32150255
http://dx.doi.org/10.1093/pm/pnz326

Ejemplares similares